Bamboos Health Care Holdings Ltd (2293) AI Stock Analysis

• Market Cap: HK$197.21M
• Dividend Yield: 8%
• Average Volume (3M): 19.31K
• Price to Earnings (P/E): 11.2
• Beta (1Y): 0.02
• Revenue Growth: -21.50%
• EPS Growth: -43.25%
• Country: HK
• Employees: 75
• Sector: Industrials
• Sector Strength: 72
• Industry: Medical - Care Facilities
• EPS (TTM): 0.02
• Shares Outstanding: 402,460,000
• 10 Day Avg. Volume: 2,658
• 30 Day Avg. Volume: 19,312
• PEG Ratio: -0.23
• Price to Book (P/B): 1.14
• Price to Sales (P/S): 2.62
• P/FCF Ratio: 6.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 75 Outperform
• Price Target: HK$0.50 ▲(0.00% Upside)

Bamboos Health Care Holdings Ltd benefits from strong profitability and efficient operations, balanced with concerns about declining revenue. The stock's positive technical indicators and attractive valuation further support its attractiveness. The stock is well-positioned for potential appreciation, given its strong financial health and favorable momentum.

Positive Factors

Strong Profit Margins

High profit margins indicate efficient cost management and a strong competitive position in the healthcare staffing market, supporting long-term profitability.

Solid Balance Sheet

A solid balance sheet with low leverage provides financial stability and flexibility, enabling the company to invest in growth opportunities and weather economic fluctuations.

Enhanced Governance

The establishment of a Nomination Committee strengthens corporate governance, aligning with best practices and potentially improving strategic decision-making and stakeholder confidence.

Negative Factors

Declining Revenue

Consistent revenue decline raises concerns about the company's ability to sustain growth and maintain its market position, potentially impacting long-term financial health.

Internal Control Issues

Internal control deficiencies can lead to compliance risks and operational inefficiencies, undermining investor confidence and potentially affecting the company's reputation and governance.

Decreasing Cash Flow

A decrease in free cash flow may limit the company's ability to invest in growth initiatives and meet financial obligations, affecting long-term operational sustainability.

Bamboos Health Care Holdings Ltd Business Overview & Revenue Model

Company Description

Bamboos Health Care Holdings Limited, an investment holding company, provides healthcare staffing solutions in Hong Kong. It offers healthcare institution support and private nursing solutions. The company also provides marketing and consulting services; and technology promotion and application services, as well as operates aesthetic clinics. It serves individuals and institutional clients, including hospitals, social service organizations, and clinics. The company was founded in 2009 and is headquartered in Tsim Sha Tsui, Hong Kong.

How the Company Makes Money

Bamboos Health Care Holdings Ltd generates revenue through its staffing services by charging fees for the placement of healthcare professionals. The company earns money by contracting with healthcare facilities that require temporary or permanent staffing solutions. These facilities pay Bamboos a fee for sourcing, vetting, and providing qualified healthcare personnel. The company may also generate additional revenue from training and consultancy services offered to both healthcare professionals and institutions, enhancing the skill set and operational efficiencies within the healthcare industry.

Bamboos Health Care Holdings Ltd Financial Statement Overview

Summary

Bamboos Health Care Holdings Ltd demonstrates strong profitability and efficient operations with high margins and a solid balance sheet. However, declining revenues over recent years raise concerns about future growth prospects. The company maintains a strong liquidity position, supporting its operations despite revenue challenges.

Income Statement

The company shows strong gross and net profit margins with a Gross Profit Margin of 89.4% and a Net Profit Margin of 32.6% for the latest period. However, the revenue has decreased significantly over the past few years, with a noticeable decline of 25.8% from 2022 to 2023 and another decline of 25.8% from 2023 to 2024. EBITDA and EBIT margins remain robust, indicating efficient cost management.

Balance Sheet

The company maintains a strong equity position with an Equity Ratio of 68.6%. The Debt-to-Equity Ratio is low at 0.29, indicating conservative leverage. However, the Return on Equity has decreased over the period, reflecting the decline in net income relative to equity. The company has maintained strong liquidity with substantial cash reserves.

Cash Flow

Free Cash Flow remains positive, although it decreased by 14.2% from 2023 to 2024. The Operating Cash Flow to Net Income Ratio is robust, showing effective conversion of income to cash. The Free Cash Flow to Net Income Ratio also remains healthy, indicating good cash generation relative to net income.

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	85.97M	94.79M	126.56M	140.29M	109.67M	72.32M
Gross Profit	50.52M	84.72M	115.12M	91.33M	82.19M	38.73M
EBITDA	33.57M	52.76M	69.85M	81.32M	78.05M	42.71M
Net Income	23.90M	30.92M	46.92M	58.62M	61.02M	30.69M
Balance Sheet
Total Assets	313.70M	318.06M	346.83M	351.35M	240.84M	181.88M
Cash, Cash Equivalents and Short-Term Investments	81.12M	81.15M	93.27M	86.27M	98.31M	101.63M
Total Debt	62.18M	63.73M	68.24M	68.96M	3.31M	5.76M
Total Liabilities	90.97M	99.74M	124.51M	140.75M	46.05M	28.61M
Stockholders Equity	222.73M	218.33M	222.32M	210.60M	194.79M	153.27M
Cash Flow
Free Cash Flow	35.74M	35.75M	41.67M	100.37M	49.42M	42.90M
Operating Cash Flow	36.57M	37.41M	41.94M	116.11M	49.44M	45.52M
Investing Cash Flow	-8.01M	-7.09M	6.92M	-111.63M	-71.38M	-29.71M
Financing Cash Flow	-32.89M	-42.44M	-41.80M	25.15M	-23.04M	-32.87M

Bamboos Health Care Holdings Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2293, the sentiment is Negative. The current price of 0.5 is above the 20-day moving average (MA) of 0.50, below the 50-day MA of 0.51, and below the 200-day MA of 0.52, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 35.97 is Neutral, neither overbought nor oversold. The STOCH value of 14.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2293.

Bamboos Health Care Holdings Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0722	78 Outperform	HK$384.46M	11.68	4.28%	7.10%	-2.88%	-22.83%
2293	75 Outperform	HK$197.21M	11.19	7.84%	8.00%	-21.50%	-43.25%
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
8357	61 Neutral	HK$84.24M	-12.03	-10.31%	―	-11.68%	-71.01%
1419	55 Neutral	HK$307.44M	11.67	3.40%	3.75%	9.07%	8.95%
8307	48 Neutral	HK$58.72M	-44.85	-19.93%	―	-2.91%	55.41%
8143	42 Neutral	HK$204.04M	-6.33	-132.60%	―	-30.45%	-734.38%

Bamboos Health Care Holdings Ltd Corporate Events

Bamboos Health Care Secures Unanimous Shareholder Approval at AGM

Bamboos Health Care Holdings Ltd announced that all resolutions proposed at their Annual General Meeting on November 28, 2025, were unanimously approved by shareholders. Key resolutions included the re-election of directors, approval of financial statements, re-appointment of the auditor, and authorization for share-related mandates. This unanimous approval reflects strong shareholder confidence and positions the company for continued stability and growth.

The most recent analyst rating on (HK:2293) stock is a Buy with a HK$0.50 price target. To see the full list of analyst forecasts on Bamboos Health Care Holdings Ltd stock, see the HK:2293 Stock Forecast page.

Bamboos Health Care Clarifies Dividend Typographical Error

Bamboos Health Care Holdings Ltd issued a clarification announcement regarding a typographical error in their annual report and circular for the year ended 30 June 2025. The proposed final dividend was incorrectly stated as HK2.5 cents per share instead of the correct amount of HK1.5 cents per share. This correction does not affect any other information in the annual report or circular.

The most recent analyst rating on (HK:2293) stock is a Buy with a HK$0.50 price target. To see the full list of analyst forecasts on Bamboos Health Care Holdings Ltd stock, see the HK:2293 Stock Forecast page.

Bamboos Health Care Holdings Ltd Announces Annual General Meeting and Strategic Resolutions

Bamboos Health Care Holdings Ltd has announced its upcoming annual general meeting scheduled for November 28, 2025, in Hong Kong. Key agenda items include the approval of financial statements, re-election of directors, auditor appointment, and a final dividend payment. Additionally, the company seeks shareholder approval for a mandate to issue new shares, which could impact its capital structure and market positioning.

The most recent analyst rating on (HK:2293) stock is a Buy with a HK$0.50 price target. To see the full list of analyst forecasts on Bamboos Health Care Holdings Ltd stock, see the HK:2293 Stock Forecast page.

Bamboos Health Care Announces Final Dividend for FY2025

Bamboos Health Care Holdings Ltd announced a final ordinary cash dividend of HKD 0.015 per share for the financial year ending June 30, 2025. The dividend reflects the company’s commitment to returning value to shareholders and is scheduled for payment on December 18, 2025, following shareholder approval on November 28, 2025.

The most recent analyst rating on (HK:2293) stock is a Buy with a HK$0.50 price target. To see the full list of analyst forecasts on Bamboos Health Care Holdings Ltd stock, see the HK:2293 Stock Forecast page.